ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

FDA News: Consolidation Plan Designed For Savings

June 5, 1998

Taxol Plus Carboplatin Increased Survival Of NSCLC In Patients 70 And Older

June 25, 2010

In Brief: Ashworth Named Center Director at UCSF

March 21, 2014

NCI Supports Development Of Reinoids for Prevention; No Magic Bullet

May 6, 1977

Guest Editorial – Power Shifts to Communities

January 9, 1976